Rheumatoid Arthritis OSCE & Ward Guide: Diagnosis, DAMP-SAFE Workup, T2T ≤ 6 Management (ACR/EULAR 2023)

1. Making the Diagnosis

Step-wise approach, you can reproduce on the wards or in a viva:

What you do	Why it matters	“Exam-ready” tips
1. Confirm persistent synovitis in ≥ 1 joint lasting ≥ 6 weeks (rule out trauma, gout, OA, viral arthritis).	Chronicity separates RA from most viral arthritides and “post-traumatic” effusions.	Ask: “When did your morning stiffness start, and how long before your hands loosen up?” A duration > 30 min is a red flag for inflammatory disease.
2. Apply the 2010 ACR/EULAR score (need ≥ 6/10 to classify RA). • Joint involvement (up to 5 points) • Serology (RF / anti-CCP; up to 3 points) • Acute-phase reactants (ESR / CRP; 1 point) • Symptom duration ≥ 6 weeks (1 point)	Most sensitive tool for early disease; you can “collect points” in any order.	Memorise with “J-SAD” (Joints, Serology, Acute phase, Duration).
3. Exclude mimics – crystal arthropathy (polarised microscopy), parvovirus (IgM), psoriatic arthritis, SLE, infective endocarditis.	Prevents anchoring bias and bad exam write-ups.	If a single knee is hot-swollen, tap it before you label it RA.
4. Baseline labs and imaging — CBC, LFT, renal panel, ESR, CRP — RF & anti-CCP (anti-CCP is more specific and prognostic) — Plain X-ray of hands & feet ± ultrasound/MRI for sub-clinical erosions	Establishes disease burden and screens for drug safety (e.g., MTX hepatotoxicity).	Ultrasound “power-Doppler signal” = active synovitis and scores bonus marks.

Scoring Grid (0 – 10 points)

Domain	How to count	Score
A. Joint involvement (maximum = 5)	Large joints = shoulders, elbows, hips, knees, ankles. Small joints = MCP, PIP, IP-thumb, MTP 2-5, wrists. Extra recognised joints (count as “small” for >10 rule): TMJ, SC, AC, CMC 1, others “reasonably expected in RA”.	• 1 large = 0 • 2-10 large = 1 • 1-3 small (± large) = 2 • 4-10 small (± large) = 3 • >10 joints with ≥ 1 small = 5 ard.eular.org
B. Serology (RF, anti-CCP) (max = 3)	• Negative both = 0 • Low-positive* either = 2 • High-positive† either = 3	assets.contentstack.iotimeofcare.com
C. Acute-phase reactants (max = 1)	Abnormal ESR or CRP = 1 (use lab ULN); both normal = 0	assets.contentstack.io
D. Duration of symptoms (max = 1)	Patient-reported synovitis ≥ 6 wk = 1; synovitis < 6 wk = 0	assets.contentstack.io

* Low-positive = > ULN but ≤ 3×ULN.† High-positive = > 3×ULN for the given assay. If the lab only reports “positive”, code it as low-positive. timeofcare.com

➡ Definite RA = total ≥ 6/10 Algorithm Cheat Sheet

Identify ≥ 1 clinical synovitis ⇨ exclude mimics.
Count joints → assign A-score.
Order same-day labs → RF, anti-CCP, ESR, CRP.
Ask: “When did this joint swelling first appear and has it ever fully disappeared?”
Sum points.• ≥ 6 → classify RA, start treat-to-target DMARD plan.• < 6 → “undifferentiated inflammatory arthritis”; monitor & re-score ± imaging.

2. Staging & Assessment of Severity

Radiographic (anatomic) stage – Steinbrocker I-IVI = no erosions, II = early erosions/joint-space loss, III = cartilage + bone destruction with deformity, IV = fibrous/bony ankylosis wheelessonline.com
Functional class – Steinbrocker Class I-IV (I = full function → IV = bed-/wheel-chair-bound). scientificspine.com
Current inflammatory activity – composite scoresDAS28-ESR / CRP• < 2.6 = remission • 2.6-3.2 = low • 3.3-5.1 = moderate • > 5.1 = high mdcalc.comAlternative: CDAI ≤ 2.8 for remission (stringent, no labs). ard.bmj.com
Prognostic flags – high anti-CCP titre, very high CRP, early erosions, extra-articular disease, smoking, seropositive nodules. These push you toward early biologic therapy.

3. Investigations—Think “DAMP-SAFE” before starting DMARDs

Purpose	Tests
Diagnosis & baseline disease burden	RF, anti-CCP, ESR/CRP; hand/feet X-ray, ultrasound or MRI if X-ray normal.
Assess Activity	DAS28 (28-joint count, ESR/CRP, patient VAS), CDAI/SDAI.
Monitor Meds	CBC, LFTs, creatinine q 4–8 weeks on csDMARDs; lipids on JAK inhibitors.
Prognosis	Baseline erosions, anti-CCP titre.
Safety Screen	Hep B/C serology, HIV, QuantiFERON-TB/Chest X-ray (biologics, JAKi), pregnancy test.
Alternative diagnoses	Serum urate, synovial aspirate crystal exam & culture.
Function & damage	Plain cervical spine flex/ext films if surgery or neuro-sx; DEXA if steroids.
Every-visit extras	Blood pressure, BMI, vaccine status (flu, pneumococcal, zoster, HPV, COVID-19).

4. Management—“T2T ≤ 6” (Treat-to-Target, achieve remission or low activity within 6 months)

4.1 Non-pharmacologic bedrockPatient education, smoking cessation, exercise/physio, Mediterranean-style diet, weight optimisation, vaccination, CV-risk & osteoporosis screening.

4.2 Pharmacologic ladder (ACR 2021 & EULAR 2023 updates) the-rheumatologist.orgard.bmj.com

Step	Drug(s) & key notes	When to escalate
1. csDMARD mono-therapy – Methotrexate 15–25 mg po/SC once weekly + folic acid 1 mg daily.	Cornerstone; give with 6–12 week uptitration. Contra-indicated? Use Leflunomide 20 mg od or Sulfasalazine 1 g bid ± Hydroxychloroquine 200–400 mg/day.	Moderate/high DAS28 after 3–6 months, or intolerance.
2. Short bridging steroid – Prednisone ≤ 10 mg/d (≤ 3 months) or intra-articular triamcinolone.	Rapid symptom control while csDMARD takes effect.	Aim to taper off completely; minimise cumulative dose.
3. Combination / add-on	MTX + bDMARD (e.g., Etanercept 50 mg SC weekly; Adalimumab 40 mg q2w; Abatacept, Tocilizumab) OR MTX + tsDMARD (e.g., Tofacitinib 5 mg bid, Upadacitinib 15 mg od).	Failure of step 1; presence of poor prognostic factors may allow direct start here (EULAR).
4. Switch class	If TNFi fails, rotate to non-TNFi biologic or JAK inhibitor; vice-versa.	Re-assess every 3 months; document DAS28 trajectory.
5. Remission taper	Consider dose reduction or spacing biologic if sustained DAS28 < 2.6 for ≥ 6 months.	Never stop all therapy abruptly; relapse rate > 50 %.

4.3 Managing common drug toxicities

Agent	Monitor / Mitigate	High-yield exam complication
MTX	CBC/LFT every 4-8 wks; folic acid 1 mg od	Hepatotoxicity, interstitial pneumonitis.
Leflunomide	LFTs; cholestyramine washout if pregnancy desired	Teratogenic, long t ½.
TNF-i	TB/HBV screening; beware demyelination, CHF	Reactivation TB is a favourite MCQ.
JAK-i	Lipids, CBC; avoid in VTE/high CV-risk	↑ Zoster, VTE/MI in > 50 y smokers.

4.4 Surgical options Synovectomy → tendon repair → joint replacement for irreversible damage (usually Steinbrocker III/IV). Early referral improves outcomes.

5. Putting it all together on exam day

Open with diagnostic criteria – quote the 2010 ACR/EULAR score.
Stage the patient – give both DAS28 and Steinbrocker stage (“Mr A has DAS28 5.4, high activity; radiographic Stage II with early erosions”).
Order “DAMP-SAFE” investigations while counselling on lifestyle.
Start MTX + folate, bridge steroids, plan first disease-activity review at 12 weeks.
Explain treat-to-target logic (“goal ≤ DAS28 2.6 by 6 months; if not, escalate to MTX + adalimumab”).
Discuss safety & vaccinations before signing off.

Check-Yourself Question: Why do we screen for latent TB before a single dose of TNF inhibitor but only repeat that screen before switching to another biologic class?(Answer: TNF blockade uniquely impairs granuloma maintenance, giving higher reactivation risk.)

Use this framework and the mnemonics “J-SAD” and “T2T ≤ 6” to recall the key steps quickly during OSCEs or on the ward.